Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

Gilead Sciences (Gilead) is a research-based biopharmaceutical company ... and Africa. Gilead is headquartered in Foster City, California, the US. For a complete picture of GS-0151’s drug-specific ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best humane stocks to invest in now. In recent years, the investment landscape has ...

We recently compiled a list of the 8 Best Humane Stocks to Invest in Now. In this article, we are going to take a look at ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

$2,440,000 of GILEAD SCIENCES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "International trade and protection ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...